In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer, with a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Pfizer’s strategic positioning in the obesity treatment market. The recent acquisition of Metsera marks a significant step for Pfizer, allowing it to re-enter the obesity space with promising long-acting GLP-1 and amylin agents that could compete effectively with existing products from major players like Lilly and Novo. The deal’s structure, which includes contingent value rights (CVRs), provides Pfizer with a de-risked opportunity to strengthen its position in this competitive market.
Furthermore, Seigerman notes that Pfizer’s shares appear undervalued compared to its U.S. BioPharma peers, with potential for top-line growth and margin expansion that is not fully appreciated by the market. The company’s strategic acquisitions, fueled by the financial gains from COVID-related products, have enhanced its pipeline, positioning Pfizer for future growth. These factors collectively support Seigerman’s optimistic outlook and Buy rating on Pfizer’s stock.
In another report released on September 13, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $27.00 price target.